Delving into the Latest Updates on Fyodorov Eye Microsurgery Complex with Synapse

概览

关联

2

项与 Fyodorov Eye Microsurgery Complex 相关的药物

Mesenchymal stem cell therapy (Stemedica Cell Technologies)

靶点-

作用机制

细胞替代物

在研机构

Stemedica Cell Technologies, Inc. [+1]

原研机构

Stemedica Cell Technologies, Inc.

在研适应症

缺血性卒中 [+2]

非在研适应症

痴呆 [+3]

最高研发阶段临床2/3期

首次获批国家/地区-

首次获批日期-

Neural stem cell therapy (Stemedica Cell Technologies)

靶点-

作用机制

细胞替代物

在研机构-

原研机构

Stemedica Cell Technologies, Inc.

在研适应症-

非在研适应症

阿尔茨海默症 [+4]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

100 项与 Fyodorov Eye Microsurgery Complex 相关的临床结果

登录后查看更多信息

0 项与 Fyodorov Eye Microsurgery Complex 相关的专利（医药）

登录后查看更多信息

5

项与 Fyodorov Eye Microsurgery Complex 相关的文献（医药）

2021-03-01·Biochemistry (Moscow)4区 · 生物学

Mitochondrial Antioxidant SkQ1 Improves Hypothermic Preservation of the Cornea

4区 · 生物学

Article

作者: Kolosova, Nataliya G ; Palchikova, Irina G ; Baturina, Galina S ; Solenov, Evgeniy I ; Katkova, Lubov E ; Iskakov, Igor A

Diseases of the cornea are a frequent cause of blindness worldwide. Keratoplasty is an efficient method for treating severely damaged cornea. The functional competence of corneal endothelial cells is crucial for successful grafting, which requires improving the media for the hypothermic cornea preservation, as well as developing the methods for the evaluation of the corneal functional properties. The transport of water and ions by the corneal endothelium is important for the viability and optic properties of the cornea. We studied the impact of SkQ1 on the equilibrium sodium concentration in the endothelial cells after hypothermic preservation of pig cornea at 4°C for 1, 5, and 10 days in standard Eusol-C solution. The intracellular sodium concentration in the endothelial cells was assayed using the fluorescent dye Sodium Green; the images were analyzed with the custom-designed CytoDynamics computer program. The concentrations of sodium in the pig corneal endothelium significantly increased after 10 days of hypothermic preservation, while addition of 1.0 nM SkQ1 to the preservation medium decreased the equilibrium concentration of intracellular sodium (at 37°C). After 10 days of hypothermic preservation, the permeability of the plasma membrane for sodium decreased in the control cells, but not in the cells preserved in the presence of 1 nM SkQ1. Therefore, SkQ1 increased the ability of endothelial cells to restore the intracellular sodium concentration, which makes SkQ1 a promising agent for facilitating retention of the functional competence of endothelial cells during cold preservation.

2020-08-01·Graefe's Archive for Clinical and Experimental Ophthalmology3区 · 医学

Tear cytokines as potential biomarkers in non-infectious uveitis: post hoc analysis of a randomised clinical trial

3区 · 医学

Article

作者: Kalinovskaya, Natalia Y ; Biryukova, Anastasia A ; Shirinsky, Ivan V ; Shirinsky, Valery S

PURPOSEThe study aimed to evaluate cytokines in tears as potential biomarkers in non-infectious uveitis.METHODSTear samples were obtained using Schirmer strips from 50 patients enrolled in a randomised controlled study of simvastatin in non-infectious uveitis and from a control group of 30 healthy participants. The concentrations of IL-6, IL-8, IL-10, and IFN-γ in tears were measured at the study's baseline and again after 8 weeks of treatment using commercial enzyme-linked immunosorbent assay kits.RESULTSThe concentrations of tears IL-6 and IL-10 were increased in patients with non-infectious uveitis in comparison with the healthy participants. Longer disease duration was associated with elevated levels of IL-6. The concentrations of the studied cytokines in tears did not correlate with the extent of eye inflammation at baseline. No link between the changes in cytokine levels and changes in clinical parameters during treatment was observed. Baseline IL-10 concentrations independently predicted the development of the clinical response to treatment at weeks 4 and 8.CONCLUSIONAlthough elevated in non-infectious uveitis patients, tear cytokine levels do not correlate with eye inflammation and are not sensitive to change after treatment. However, the level of IL-10 may be a predictive biomarker of response to the treatment of uveitis.TRIAL REGISTRATIONNCT04183387.

2017-12-02·Current Eye Research4区 · 医学

Simvastatin as an Adjunct to Conventional Therapy of Non-infectious Uveitis: A Randomized, Open-Label Pilot Study

4区 · 医学

Article

作者: Shirinsky, Valery S. ; Shirinsky, Ivan V. ; Biryukova, Anastasia A.

PURPOSEStatins have been shown to reduce ocular inflammation in animal models of uveitis and to prevent development of uveitis in observational studies. There have been no experimental human studies evaluating statins' efficacy and safety in uveitis. In this study, we aimed to investigate efficacy and safety of simvastatin in patients with uveitis.METHODSFor this single-center, open-label, randomized study, we enrolled patients with acute non-infectious uveitis. The patients were randomized to receive 40 mg simvastatin per day for 2 months in addition to conventional treatment or conventional treatment alone. The studied outcomes were the rate of steroid-sparing control of ocular inflammation, measures of ocular inflammation, intraocular pressure, and visual acuity.RESULTSFifty patients were enrolled in the study. Twenty-five patients were randomly assigned to receive simvastatin with conventional treatment and 25 to conventional treatment alone. Simvastatin was associated with significantly higher rates of steroid-sparing ocular inflammation control, decrease in anterior chamber inflammation, and improvement in visual acuity. The treatment was well tolerated, no serious adverse effects were observed.CONCLUSIONSOur findings suggest that statins may have therapeutic potential in uveitis. These results need to be confirmed in double-blind, randomized, controlled studies.

100 项与 Fyodorov Eye Microsurgery Complex 相关的药物交易

登录后查看更多信息

100 项与 Fyodorov Eye Microsurgery Complex 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

其他

2

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Neural stem cell therapy (Stemedica Cell Technologies)	糖尿病性视网膜病变更多	无进展
Mesenchymal stem cell therapy (Stemedica Cell Technologies)	糖尿病性视网膜病变更多	无进展